2024-11-19 | Company
Company Report 2023
The year 2023 has proven successful, especially in the United States. Revenues increased by 50 percent, with significant improvements in profit margins.
2024-11-19 | Company
The year 2023 has proven successful, especially in the United States. Revenues increased by 50 percent, with significant improvements in profit margins.
2024-11-14 | Company
Sever Pharma Solutions is proud to be prominently featured in the 2024 Citeline Annual Report on Medicon Valley.
2024-08-30 | Company
We are happy to announce that Stefan Petersson has been appointed as Global HR Director.
2024-08-01 | Company
Here you can read the latest press release from The Global Fund and The Children’s Investment Fund Foundation, explaining how PrEP rings, manufactured in Sweden by Sever Pharma Solutions, make a difference for women in Africa.
2024-07-05 | Company
Our ability to achieve business success and deliver long-term customer value depends on our systematic and strategic efforts to monitor and enhance our global sustainability impact.
2023-12-21 | Company
Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in controlled release systems for highly potent drugs is pleased to announce the successful attainment of the Drug Enforcement Administration (DEA) license for its site in Putnam, CT.
2023-12-19 | Company
During 2022, we initiated the expansion of the R&D capacity at our US site in Putnam and increased our capabilities with a new line for aseptic fill and finish. Read the full company report.
2023-10-18 | Company
We pleased to announce the approval by the Swedish Health authorities of its state-of-the-art aseptic filling line for syringes, specifically designed for high potent injectable drugs, at its Malmo site.
2023-10-11 | Company
We are happy to announce that Kristian Ahlgren has been appointed as Director of Supply Chain Management.
2023-09-21 | Company
[Putnam, CT, USA - Sever Pharma Solutions, a leading pharmaceutical contract development and manufacturing organization (CDMO), has announced the groundbreaking of its new high potency active pharmaceutical ingredients (HPAPI) manufacturing suites.